KaiGenesis Labs to Revolutionize Synthetic Discovery
Launched with angel investor backing in early 2026, KaiGenesis is making significant headway in developing its next groundbreaking stereoisomer descriptor NN models. In its mission to lead modern, de novo synthetic therapeutic design and explore the frontiers of computational xenobiologics,…